What's New
| Page summary | Text size | Search | |
What’s New keeps you up-to-date with the latest InCirculation.net activities.
| | |
27 November 2009The PLATO trial enveiled ticagrelor as the first antiplatelet therapy to achieve a significant reduction in CV mortality compared with clopidogrel across the spectrum of ACS. Freek Verheugt reviews the field - CURE, COMMIT, TRITON-TIMI 38 and the CHAMPION trials. Did PLATO herald a new dawn in antiplatelet therapy?
25 November 2009The Indian Polycap Study (TIPS), a proof-of-concept, primary prevention trial, demonstrated the potential cardiovascular and economic benefit of a multi-drug regimen including a beta blocker, an ACE inhibitor, a statin, a thiazide and aspirin. This is no ‘magic bullet’, though. As K. Srinath Reddy asserts in his Editorial, there are outstanding questions, and only further study will ascertain whether such a treatment can reduce the risk of major cardiovascular events.
20 January 2009The delivery of effective evidence-based treatments for primary and secondary prevention is now one of the key strategies in controlling coronary heart disease burden, but there is still no consensus on what is needed and what are the priorities. Martin O’Flaherty and Simon Capewell discuss the results of the EUROACTION trial, which provides insight on what could be achieved by targeting high-risk patients.
| |
